Skip to content
Newshub

SOMAÍ Expands Partnership with Dascoli Pharma AG to Launch Mint Oral Solutions Line in Switzerland

Jan. 05, 2026 by SOMAÍ Pharmaceuticals

SOMAÍ, a leading EU-GMP-certified vertically integrated Multi-Country Operator (MCO) specializing in cannabinoid-based medicines, announces the launch of its Mint Oral Solutions line in Switzerland, marking the next phase of its collaboration with Dascoli Pharma AG, a Switzerland-based pharmaceutical company specializing in the supply, distribution, and professional training of medical cannabis.

Following the successful introduction of the Essentuals line last year, the expansion of SOMAÍ and Dascoli Pharma AG’s partnership underscores a shared commitment to advancing patient access to innovative cannabinoid-based medicines in Switzerland.

The Mint Oral Solutions line has been developed to combine pharmaceutical precision with improved patient compliance and treatment adherence. Created using SOMAÍ’s advanced purification process, the formulations feature a refreshing peppermint terpene mix that offers a more pleasant experience for patients requiring long-term treatment. Each product in the line maintains consistent cannabinoid profiles, high bioavailability, and EU-GMP-certified quality, reflecting SOMAÍ’s commitment to innovation and patient-centric design.

“Our ongoing collaboration with Dascoli Pharma AG allows SOMAÍ to continue expanding access to our cannabinoid formulations through a trusted partner that shares our vision of pharmaceutical integrity and medical compliance,” said Michael Sassano, CEO of SOMAÍ Pharmaceuticals. “The introduction of the Mint Oral Solutions line builds on the success of our Essentuals range and reinforces SOMAÍ’s position as a leader in EU-GMP cannabinoid-based medicines.”

With the broadest EU-GMP-certified extract portfolio in Europe, SOMAÍ develops a diverse range of cannabinoid-containing pharmaceutical products that combine innovation, science, and patient care. Each formulation is designed to meet the highest pharmaceutical standards while addressing the evolving therapeutic needs of patients and healthcare providers.

“Dascoli Pharma AG is proud to continue building on our successful collaboration with SOMAÍ through the introduction of the Mint Oral Solutions line,” said Andrew Petronanos, Founder & CEO of Dascoli Pharma AG. “The patient-oriented design and scientific rigor behind SOMAÍ’s formulations align perfectly with our mission to ensure Swiss patients have access to safe, effective, and innovative cannabinoid-based therapies.”

Together, SOMAÍ and Dascoli Pharma AG are strengthening the foundation of medical cannabis accessibility in Switzerland—continuing to set new standards for safety, consistency, and patient care.

About SOMAÍ 

SOMAÍ is a leading EU-GMP vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract and flower portfolio.

At SOMAÍ, we are building a leading global brand with the most robust pipeline of innovative cannabis-based therapeutics. We envision a world where people live a healthy lifestyle empowered by natural cannabis medicine.

SOMAÍ owns a state-of-the-art manufacturing facility, SOMAÍ Pharmaceuticals, and indoor cultivation NovaSoma in Lisbon, Portugal, and has global sales teams in the largest medical cannabis markets. We are continuing to make acquisitions and global brand partnerships that make us one of a few and the first European-based vertically integrated companies in the EU able to cater to the diverse needs of fast-growing global cannabis markets.

About Dascoli Pharma

Dascoli Pharma AG is a Switzerland-based pharmaceutical company specializing in the supply, distribution, and professional training of medical cannabis. In addition to its extensive wholesale distribution network, Dascoli operates Stauffacher Apotheke, a Zürich-based pharmacy dedicated to dispensing high-quality, GMP-certified cannabinoid medicines. Founded in 2022 by Andrew Petronanos, an experienced entrepreneur in regulated markets, Dascoli Pharma is committed to operational excellence, regulatory compliance, and patient-centric care.

With a strong focus on education and clinical expertise, Dascoli Pharma is supported by a robust scientific leadership structure with deep experience in cannabinoid therapies and regulatory development. This foundation enables the company to provide high-quality medical education, evidence-based guidance, and meaningful support to healthcare professionals, thereby facilitating the responsible adoption of cannabinoid-based treatments for patients.